Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on December 29, 2021. The filing addresses Item 5.02 regarding the departure of directors, election of directors, appointment of officers, and compensatory arrangements. Specifically, the Compensation Committee approved a new compensation structure for non-employee directors to attract and retain qualified individuals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director compensation arrangements rather than operational financial performance.
Material Changes
The primary material change is the approval of the following Non-Employee Director Compensation package effective December 29, 2021:
- Base Compensation: Each non-employee director receives a cash retainer fee of $25,000.
- Equity Grant: Each non-employee director receives a 5-year option to purchase $25,000 worth of common stock (177,233 shares) with an exercise price of $0.1460. These options vest 100% on the one-year anniversary of the grant date.
- Committee Chair Fees: The Audit Committee Chair receives an additional cash fee of $12,500. The Compensation Committee Chair receives an additional cash fee of $7,500.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on business strategy, specific risks, or contingencies beyond the standard disclosure of the compensation approval.
Key Facts for Investor Verification
- Verify the total number of non-employee directors to calculate the aggregate cash and equity cost of this new compensation plan.
- Confirm the impact of the 177,233 share option grants per director on total outstanding share count and potential dilution.
- Review the company's cash position to ensure it can support the immediate cash retainer fees and future committee chair fees.
- Check subsequent filings to confirm if any directors declined the offer or if the vesting schedule was modified.